Amgen plans launch of Eylea biosimilar after court ruling
2 days ago · Dive Brief: Amgen is taking the risky step of preparing to launch a biosimilar version of Regeneron’s blockbuster Eylea drug after winning a victory in an ongoing legal battle. The U.S. Court of Appeals for the Federal Circuit on Tuesday lifted a temporary injunction that barred Amgen from introducing the medicine, rejecting Regeneron’s ...
Legal win leads Amgen to at-risk launch of Eylea biosimilar
17 hours ago · The bold decision puts Amgen at risk of hefty damages if future rounds in the litigation go Regeneron's way, offset by the rewards that could follow from the first launch of a lower-cost, copycat ...
Regeneron loses bid to block Amgen's Eylea biosimilar launch in …
2 days ago · Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...
Amgen pledges to launch Eylea biosim after legal win—but Regeneron …
1 day ago · The court did, however, grant Regeneron’s request to expedite the appeal process. Now, Amgen will need to submit its brief on the matter no later than Nov. 4 and Regeneron by Nov. 13 ahead of ...
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Sept 23 (Reuters) - Regeneron (REGN.O) cannot immediately block U.S. sales of rival Amgen's (AMGN.O) proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on...
Regeneron's Eylea biosimilar fight heats up after court ruling - STAT
Sep 24, 2024 · Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
Regeneron Fails to Block Amgen's Eylea Biosimilar During Appeal
2 days ago · A three-judge panel of the US Court of Appeals for the Federal Circuit denied Regeneron’s bid to block Amgen from launching Pavblu, its biosimilar of the blockbuster eye-disease drug, pending Regeneron’s appeal, according to an order issued Tuesday. Shares of Regeneron dropped by as much 5.1% in the wake of the ruling. “Without ...
Regeneron Appeals After Judge Declines to Block Amgen Biosimilar
Regeneron Pharmaceuticals Inc. quickly appealed a judge’s order declining to block Amgen Inc.'s biosimilar version of its blockbuster eye drug Eylea while a patent-infringement suit continues.
Regeneron falls after judge denies injunction blocking Amgen Eylea ...
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen biosimilar version of Regeneron's blockbuster...
Amgen's Formulation of Eylea Biosimilar Saved It From Injunction
Oct 2, 2024 · Amgen Inc. avoided Regeneron Pharmaceuticals Inc.’s attempt to block its Eylea biosimilar because a federal judge in West Virginia found its version of the blockbuster eye-disease drug—unlike the four Regeneron successfully blocked—lacks a required separate buffer, according to a redacted order.
- Some results have been removed